Meeting
2023 ASCO Genitourinary Cancers Symposium
Clinical outcomes of patients with metastatic renal cell carcinoma who discontinued nivolumab +/- ipilimumab therapy electively or due to toxicity.
Authors
Jessica Heejin Yoo
University of Washington, Seattle, WA
Jessica Heejin Yoo , Duncan Hussey , Evan Gross , Sarah P. Psutka , Scott S. Tykodi , John A. Thompson , Evan Thomas Hall
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 625)
DOI
10.1200/JCO.2023.41.6_suppl.625
Abstract #
625
Poster Bd #
E15
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Estimating treatment-free survival (TFS) over extended follow-up in patients (pts) with advanced melanoma (MEL) treated with immune-checkpoint inhibitors (ICIs): Five-year follow-up of CheckMate 067.
First Author: Meredith M. Regan
Poster
2024 ASCO Genitourinary Cancers Symposium
Combination nivolumab and ipilimumab with and without camu camu in first-line treatment of metastatic renal cell carcinoma (mRCC).
First Author: Regina Barragan-Carrillo
Poster
2023 ASCO Genitourinary Cancers Symposium
Association between time-of-day of the immune checkpoint inhibitor (ICI) infusion and disease outcomes among patients with metastatic renal cell carcinoma (mRCC).
First Author: Nazli Dizman
Poster
2022 ASCO Annual Meeting
A phase I trial to evaluate the biologic effect of CBM588 (Clostridium butyricum) in combination with cabozantinib plus nivolumab for patients with metastatic renal cell carcinoma (mRCC).
First Author: Luis A Meza